Outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface dissemination from ovarian neoplasms

American Journal of Surgery

Volumn 202, Issue 4, 2011, Pages 481-486

  Parson, E Nicole ^a   Lentz, Samuel ^a   Russell, Greg ^a   Shen, Perry ^a   Levine, Edward A ^a   Stewart IV, John H ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Carboplatin; Hyperthermic intraperitoneal chemotherapy; Mitomycin C; Ovarian cancer; Paclitaxel; Peritoneal surface malignancy

Indexed keywords

CARBOPLATIN; MITOMYCIN C; PACLITAXEL; ANTINEOPLASTIC AGENT; MITOMYCIN;

ADULT; AGED; ARTICLE; BLEEDING; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; COHORT ANALYSIS; CYTOREDUCTIVE SURGERY; DATA BASE; HUMAN; HYPERTHERMIC THERAPY; MAJOR CLINICAL STUDY; METASTASIS; OUTCOME ASSESSMENT; OVARY CANCER; PEROPERATIVE COMPLICATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; FACTUAL DATABASE; FEMALE; INFUSION; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; OVARY TUMOR; PATHOLOGY; PERITONEUM; PERITONEUM TUMOR; REGIONAL PERFUSION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; COMBINED MODALITY THERAPY; DATABASES, FACTUAL; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; INFUSIONS, PARENTERAL; MIDDLE AGED; MITOMYCIN; OVARIAN NEOPLASMS; PACLITAXEL; PERITONEAL NEOPLASMS; PERITONEUM;

EID: 84856403740     PISSN: 00029610     EISSN: 18791883     Source Type: Journal    
DOI: 10.1016/j.amjsurg.2011.02.004     Document Type: Article

References (26)

1. Chua TC, Robertson G, Liauw W, et al. Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: systematic review of current results. J Cancer Res Clin Oncol 2009;135:1637-45.
2. Levanon K, Crum C, Drapkin R. New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol 2008;26: 5284-93.
3. Bookman MA, McGuire WP III, Kilpatrick D, et al. Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group. J Clin Oncol 1996;14:1895-902. (Pubitemid 26185464)
4. Di GA, Naticchioni E, Biacchi D, et al. Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer. Cancer 2008;113:315-25.
5. Deraco M, Rossi CR, Pennacchioli E, et al. Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion in the treatment of recurrent epithelial ovarian cancer: a phase II clinical study. Tumori 2001;87:120-6. (Pubitemid 32660378)
6. Bae JH, Lee JM, Ryu KS, et al. Treatment of ovarian cancer with paclitaxel-or carboplatin-based intraperitoneal hyperthermic chemotherapy during secondary surgery. Gynecol Oncol 2007;106:193-200. (Pubitemid 46898592)
7. Armstrong DK. Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist 2002;7(suppl):20-8.
8. Gori J, Castano R, Toziano M, et al. Intraperitoneal hyperthermic chemotherapy in ovarian cancer. Int J Gynecol Cancer 2005;15:233-9. (Pubitemid 40396958)
9. Cotte E, Glehen O, Mohamed F, et al. Cytoreductive surgery and intraperitoneal chemo-hyperthermia for chemo-resistant and recurrent advanced epithelial ovarian cancer: prospective study of 81 patients. World J Surg 2007;31:1813-20. (Pubitemid 47283201)
10. Pomel C, Ferron G, Lorimier G, et al. Hyperthermic intra-peritoneal chemotherapy using oxaliplatin as consolidation therapy for advanced epithelial ovarian carcinoma. Results of a phase II prospective multi-centre trial. CHIPOVAC study. Eur J Surg Oncol 2010;36:589-93.
11. Bristow RE, Gossett DR, Shook DR, et al. Recurrent micropapillary serous ovarian carcinoma. Cancer 2002;95:791-800.
12. Stewart JH, Shen P, Levine EA. Intraperitoneal hyperthermic chemotherapy: an evolving paradigm for the treatment of peritoneal surface malignancies. Exp Rev Anticancer Ther 2008;8:1809-18.
13. Dedrick RL, Flessner MF. Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure. J Natl Cancer Inst 1997;89:480-7. (Pubitemid 27147264)
14. Dedrick RL. Interspecies scaling of regional drug delivery. J Pharm Sci 1986;75:1047-52. (Pubitemid 17216548)
15. Flessner MF, Dedrick RL, Schultz JS. A distributed model of peritoneal-plasma transport: theoretical considerations. Am J Physiol 1984; 246:R597-607. (Pubitemid 14137809)
16. Kuzuya T, Yamauchi M, Ito A, et al. Pharmacokinetic characteristics of 5-fluorouracil and mitomycin C in intraperitoneal chemotherapy. J Pharm Pharmacol 1994;46:685-9.
17. Speyer JL, Collins JM, Dedrick RL, et al. Phase I and pharmacological studies of 5-fluorouracil administered intraperitoneally. Cancer Res 1980;40:567-72. (Pubitemid 10174869)
18. Israel VK, Jiang C, Muggia FM, et al. Intraperitoneal 5-fluoro-2'-deoxyuridine (FUDR) and (S)-leucovorin for disease predominantly confined to the peritoneal cavity: a pharmacokinetic and toxicity study. Cancer Chemother Pharmacol 1995;37:32-8.
19. Ozols RF, Young RC, Speyer JL, et al. Phase I and pharmacological studies of adriamycin administered intraperitoneally to patients with ovarian cancer. Cancer Res 1982;42:4265-9. (Pubitemid 13198596)
20. Bartlett DL, Buell JF, Libutti SK, et al. A phase I trial of continuous hyperthermic peritoneal perfusion with tumor necrosis factor and cisplatin in the treatment of peritoneal carcinomatosis. Cancer 1998;83: 1251-61. (Pubitemid 28419081)
21. Markman M, Kelsen D. Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma. J Cancer Res Clin Oncol 1992;118:547-50.
22. Markman M, Brady MF, Spirtos NM, et al. Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic Oncology Group Study. J Clin Oncol 1998;16:2620-4. (Pubitemid 28363024)
23. Dikomey E, Franzke J. Effect of heat on induction and repair of DNA strand breaks in X-irradiated CHO cells. Int J Radiat Biol 1992;61: 221-33.
24. Roti Roti JL, Kampinga HH, Malyapa RS, et al. Nuclear matrix as a target for hyperthermic killing of cancer cells. Cell Stress Chaperones 1998;3:245-55. (Pubitemid 29051824)
25. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354:34-43. (Pubitemid 43048949)
26. Jaaback K, Johnson N. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev 2006;CD005340.